Please login to the form below

Exondys 51

This page shows the latest Exondys 51 news and features for those working in and with pharma, biotech and healthcare.

FDA rejects Sarepta’s new Duchenne drug over safety fears

Vyondys 53 (golodirsen) follows Exondys 51, the first and currently only disease-modifying treatment approved in the US for the inherited muscle-wasting disease. ... Sarepta gained approval for Exondys 51 three years ago amid controversy about its lack

Latest news

FDA will maintain the pace, vows Woodcock, but warns of skills gap

These cases have, of course, not been without controversy – one of the most notable being the approval of Sarepta’s Duchenne treatment Exondys 51 in 2016, despite questionable data.
Duchenne UK backs Evox dystrophin delivery project

At the moment that includes already-market drugs that skip over or ignore the mutation in the dystrophin gene – such as PTC Therapeutics’ Translarna (ataluren) and Sarepta’s Exondys 51 (eteplirsen) –
CHMP backs Spark’s Luxturna, but rejects Sarepta again

Eteplirsen was approved in the US as Exondys 51 in 2016, although the decision came after FDA reviewers recommended that the drug be rejected as the evidence for its benefits was ... which there was no meaningful difference between Exondys and placebo in
Pfizer abandons antibody for Duchenne

News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics
Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Sarepta has made its name by launching the first ever FDA approved treatment for Duchenne muscular dystrophy, Exondys 51, and is now looking to expand its pipeline into other rare disease ... Sarepta has also just announced rising sales of Exondys 51,

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
Europe vs the US: New drug product approvals

Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US
Deal Watch February 2017

Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Senior Medical Writer: Competitive salary plus benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Events Executive: DOE

Client Services Director- Flexible Working: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...